Jamaica Plain, MA, United States of America

Roberto A Maldonado

This inventor holds 19 USPTO granted patents and 39 published patent applications, plus 8 CIPO patents and 7 EPO patents, primarily in Synthetic Nanocarriers. Top assignee: Selecta Biosciences, Inc.. Active years: 2014-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Roberto A Maldonado. Retrieved from https://idiyas.com/inventor/roberto-a-maldonado

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 39)

% Patents Active = 84.2

CIPO Patents = 8 (Patent Applications = 10)

EPO Patents = 7 (Patent Applications = 18)

Average Co-Inventor Count = 1.9

ph-index = 11

Forward Citations = 435(Granted Patents)

Location History:

Berkeley, CA (US) (2022)
Jamaica Plain, MA (US) (2014 - 2023)

Company Filing History:

19 out of 32

Selecta Biosciences, Inc.

patents

Years Active: 2014-2023

Loading Chart...

Areas of Expertise:

Tolerogenic

Synthetic Nanocarriers

Allergy Therapy

Immunosuppressants

Antigen-Specific Tolerance

CD8+ Regulatory T Cells

Humoral Immune Responses

Therapeutic Macromolecules

Anaphylaxis Prevention

Regulatory B Cells

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11779641 - Tolerogenic synthetic nanocarriers for allergy therapy (2023-10-10),

2. 11717569 - Tolerogenic synthetic nanocarriers (2023-08-08),

3. 11298342 - Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity (2022-04-12),

4. 11235057 - Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses (2022-02-01),

5. 10668053 - Tolerogenic synthetic nanocarriers to reduce or prevent anaphylaxis in response to a non-allergenic antigen (2020-06-02),

6. 10441651 - Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells (2019-10-15),

7. 10434088 - Methods related to administering immunosuppressants and therapeutic macromolecules at a reduced pharmacodynamically effective dose (2019-10-08),

8. 10420835 - Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells (2019-09-24),

9. 10357483 - Methods comprising dosing combinations for reducing undesired humoral immune responses (2019-07-23),

10. 10357482 - Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity (2019-07-23),

11. 10039822 - Method for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses (2018-08-07),

12. 10004802 - Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells (2018-06-26),

13. 9993548 - Tolerogenic synthetic nanocarriers for inducing regulatory B cells (2018-06-12),

14. 9987354 - Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells (2018-06-05),

15. 9295718 - Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins (2016-03-29),

Title: Exploring the Innovations of Roberto A. Maldonado in Allergy Therapy

Introduction: Roberto A. Maldonado, a prominent inventor based in Jamaica Plain, MA, has made significant contributions to the field of allergy therapy. With a remarkable portfolio of 19 patents, his work primarily focuses on developing innovative therapeutic solutions to improve the lives of those suffering from allergies.

Latest Patents: Two of Maldonado's latest patents demonstrate his cutting-edge approach to allergy therapy. The first, titled "Tolerogenic Synthetic Nanocarriers for Allergy Therapy," discloses synthetic nanocarrier compositions and related methods that incorporate immunosuppressants and MHC Class II-restricted epitopes of an allergen. These innovations provide tolerogenic immune responses specific to the allergen, offering a new frontier in allergy treatment. The second patent, "Tolerogenic Synthetic Nanocarriers," relates to compositions featuring synthetic nanocarriers and immunosuppressants that foster immune suppressive effects. These compositions can also include antigens, leading to antigen-specific tolerogenic immune responses that may revolutionize existing allergy treatments.

Career Highlights: Roberto A. Maldonado is currently associated with Selecta Biosciences, Inc., a company dedicated to advancing the field of immunotherapy and improving patient care. His expertise in developing novel therapeutic approaches has garnered recognition within scientific communities and has the potential to transform allergy treatment.

Collaborations: Throughout his career, Maldonado has collaborated with esteemed colleagues, including Christopher C. Fraser and Takashi Kei Kishimoto. These partnerships have facilitated the exchange of ideas and innovation, contributing to the development of cutting-edge solutions in allergy therapy.

Conclusion: Roberto A. Maldonado's contributions to the field of allergy therapy through his patents and collaborations underscore the importance of innovation in healthcare. His work not only enhances our understanding of allergic responses but also paves the way for more effective treatments, thereby improving the quality of life for individuals with allergies.

Profile summary based on public USPTO records.